Yi Hsiang Huang

Yi Hsiang Huang

National Taiwan University - Taipei / Taiwan
Engineering & Technology / Electrical & Electronic Engineering
AD Scientific Index ID: 411504
國立台灣大學
person_outline Yi Hsiang Huang's MOST POPULAR ARTICLES
1-) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial,The Lancet 389 (10064), 56-66, 2017 -
2-) NASH limits anti-tumour surveillance in immunotherapy-treated HCC,Nature 592 (7854), 450-456, 2021 -
3-) Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma,Journal of hepatology 51 (5), 890-897, 2009 -
4-) Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis BYH Huang, LT Hsiao, YC Hong, TJ Chiou, YB Yu, JP Gau, CY Liu, ...Journal of Clinical Oncology 31 (22), 2765-2772, 20133732013
5-) Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trialRS Finn, P Merle, A Granito, YH Huang, G Bodoky, M Pracht, O Yokosuka, ...Journal of hepatology 69 (2), 353-358, 20183632018